A landmark study published in The Lancet confirms that England’s national HPV vaccination program has achieved a 100% reduction in cervical cancer mortality among women aged 20 to 24. Researchers analyzed population data from 2020 through 2024 for cohorts vaccinated at ages 12 and 13 starting in 2008.
The data reveals zero recorded deaths in this demographic during the study period. Without immunization, statistical models predicted approximately 23 fatalities, representing a complete prevention of expected mortality. Cumulatively, the vaccination initiative has prevented an estimated 200 cervical cancer deaths across all age groups up to the end of 2024.
Mortality reductions remain significant in slightly older cohorts. Women aged 25 to 29 experienced a 69% decrease in death rates, while those aged 30 to 34 saw a 63% reduction. These outcomes correlate directly with historical vaccine uptake rates, which reached nearly 90% for the youngest cohort before the pandemic.
Researchers emphasize that high coverage provides a feasible pathway toward the WHO Sustainable Development Goal of eliminating cervical cancer as a public health threat. The findings underscore the critical necessity of maintaining robust adolescent vaccination programs globally to replicate England’s success.